| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 137, 572-579, Copyright © 1996 by Endocrine Society
ARTICLES |
TO Bruhn, JM Rondeel, TG Bolduc, LG Luo and IM Jackson
Department of Medicine, Brown University School of Medicine, Rhode Island Hospital, Providence 02903, USA.
The present studies were undertaken to investigate the effect of 5- bromo-2'-deoxyuridine (BrdU; 50 microM) or forskolin/3-isobutyl-1- methylxanthine (F/I; 10/500 microM) on TRH gene expression in cultured fetal diencephalic cells. BrdU as well as drugs such as F/I that raise intracellular cAMP levels had been previously termed differentiating agents because they cause morphological and functional differentiation of IMR-32 neuroblastoma cells. We postulated that neurons of fetal diencephalons may remain relatively undifferentiated in vitro and that this might be the reason for low or undetectable TRH production. We hypothesized that treatment with differentiating agents might increase neuropeptide expression. Both BrdU and F/I dramatically (P < 0.01) raised intracellular TRH and pro-TRH messenger RNA concentrations in cultured diencephalic neurons. Although a short BrdU exposure during the first 4 days of culture was sufficient to irreversibly change TRH neurons and to cause maintenance of high TRH levels after withdrawal of the drug, F/I had to be present continuously throughout the observation period of 16 days to significantly elevate TRH expression. This suggests that BrdU and F/I act at different intracellular sites to activate TRH expression in cultured diencephalic neurons. The reduction of glial cells that occurs concurrent with the BrdU treatment was not observed after F/I exposure, and therefore, this effect does not appear to be a key factor for the induction of TRH expression. As the intracellular accumulation of somatostatin and arginine vasopressin, which were determined in parallel, was similarly enhanced after treatment with BrdU or F/I, our culture system might provide a valuable tool for the study of these and possibly other neuropeptides in vitro.
This article has been cited by other articles:
![]() |
E. A. Nillni, F. Aird, N. G. Seidah, R. B. Todd, and J. I. Koenig PreproTRH178-199 and Two Novel Peptides (pFQ7 and pSE14) Derived from Its Processing, Which Are Produced in the Paraventricular Nucleus of the Rat Hypothalamus, Are Regulated during Suckling Endocrinology, February 1, 2001; 142(2): 896 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fekete, E. Mihaly, L.-G. Luo, J. Kelly, J. T. Clausen, Q. Mao, W. M. Rand, L. G. Moss, M. Kuhar, C. H. Emerson, et al. Association of Cocaine- and Amphetamine-Regulated Transcript-Immunoreactive Elements with Thyrotropin-Releasing Hormone-Synthesizing Neurons in the Hypothalamic Paraventricular Nucleus and Its Role in the Regulation of the Hypothalamic-Pituitary-Thyroid Axis during Fasting J. Neurosci., December 15, 2000; 20(24): 9224 - 9234. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Nillni, R. Steinmetz, and O. H. Pescovitz Posttranslational Processing of Progrowth Hormone-Releasing Hormone Endocrinology, December 1, 1999; 140(12): 5817 - 5827. [Abstract] [Full Text] |
||||
![]() |
T. W. Kim, E. A. H. Beckett, R. Hanna, S. D. Koh, T. Ordog, S. M. Ward, and K. M. Sanders Regulation of pacemaker frequency in the murine gastric antrum J. Physiol., January 1, 2002; 538(1): 145 - 157. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |